Endpoints News
Post-Hoc Live
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com
Besuch unbedingt die Website des Podcasts und unterstütze die Macher: podcasters.spotify.com
Autor
Endpoints News
Kategorie
Podcast-Website
Neueste Folge
4. Nov 2026
Wo hören?
Podcasts in der App Replaio Radio Bald verfügbarPodcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts
Folgen
Fewer drugs, more chaos: One year under the new FDA 08.01.2026 32:51
It was a chaotic first year for this Trump administration’s FDA. The agency is down thousands of staff. Leadership was unstable . Industry insiders say they worry about the regulatory environment. What’s next? We’re joined by Holly Fernandez Lynch, an assistant professor of medical ethics at University of Pennsylvania's medical school and an FDA expert, to take stock of the past year at the FD...
Biopharma’s Winners and Losers of 2025 18.12.2025 30:31
The Endpoints newsroom has spent the past few weeks taking stock of the year and picking our 2025 biopharma winners and losers. Who (or what) was up, down, or on the rebound in 2025? We’ll reveal our picks and send you off into the holidays in style.
Reality check-ing biotech — with Derek Lowe 20.11.2025 41:34
Derek Lowe is one of the biopharma industry’s most prolific commentators — in just the past month, he’s written about generic drug manufacturing, Sarepta, and the TrkB receptor in his column, In the Pipeline. He joins Post-Hoc Live to talk about the state of drug discovery, being a skeptic, and what he has his eye on next.
M&A, MFN, and the view from the UK — with the FT’s Hannah Kuchler 04.11.2025 29:01
The relationship between big pharma and the UK turned south this year. Companies like Eli Lilly and Bristol Myers Squibb want the NHS to pay more for drugs, and others are playing hardball by pulling investments and sharply criticizing the government. And every action is wrapped up in the companies' “most favored nation” negotiations with the Trump administration. Ahead of the Financial Times’...
The plan to make more custom CRISPR therapies — w Kiran Musunuru & Rebecca Ahrens-Nicklas 03.11.2025 36:09
In February, a team of scientists achieved a long-held scientific goal — creating a bespoke CRISPR editing therapy to treat a single patient with a unique genetic mutation. “Baby KJ” got his own custom treatment only six months after he was born. Now, Rebecca Ahrens-Nicklas, a pediatrician and gene therapy scientist at CHOP, and Kiran Musunuru, a UPenn gene editing scientist, have a plan to replic...
The fight over Metsera 03.11.2025 31:06
The obesity wars just got spicier. Today, a month after Pfizer said it would buy Metsera, Novo Nordisk swooped in with its own bid for the cardiometabolic drug developer. Metsera says Novo’s offer is “superior.” Pfizer says it’s breaking their terms. We’ll tell you what comes next on Post-Hoc Live with BMO Capital Markets Head of Healthcare Research Evan Seigerman.
Is the biotech market…back? — with Tim Opler and John Carroll 15.10.2025 32:06
Don’t look now, but there are signs of life in the biotech market. The XBI has been ticking up. There were 22 M&A deals in Q3, according to John Carroll’s analysis with DealForma, and deal values are already close to the totals from all of 2024. Is it a mirage, or is the worst really over? And how much will we jinx things by saying it out loud? John and Tim Opler, Managing Director at Stifel's...
Zooming out on AI in biopharma — with Vijay Pande 07.10.2025 38:16
Vijay Pande left Andreessen Horowitz this summer after 11 years as a life sciences investor. Now, he’s building a new firm focused on AI. He joins Post-Hoc Live to take the 10,000-foot view of AI in biotech and Silicon Valley: what do investors get right and wrong about biotech? What are the business models for AI in biopharma? Which moonshot project will stick? We’ll continue the conversation nex...
This week in Washington: TrumpRx, MFN pricing, tariffs, and more 01.10.2025 42:29
On Tuesday, the Trump administration announced that it had cut a deal with Pfizer on drug pricing and tariffs, and said it’ll launch a government website called TrumpRx where people can purchase cheaper drugs. But there are a lot of lingering questions: How big might Medicaid discounts be? What role will insurance play in the direct-to-consumer website? How are negotiations going with other drugma...
Scott Gottlieb on what it would take to compete with China's biotech rise 26.09.2025 33:53
What would it take for US biotech to match the speed and cost of China? Former FDA commissioner Scott Gottlieb, who now works as an investor and board member, will talk about how the US can play defense against China's surging biotech startup ecosystem by moving faster and smarter, and if we're making steps toward doing so, or moving backward.
Which digital health tools are worth the cost? — with Caroline Pearson 16.09.2025 30:52
There are hundreds of digital health tools out there claiming they can do everything from manage diabetes to treat depression. But unlike drugs or devices, these tools don’t have to prove they work before they go on the market. Caroline Pearson, executive director at the Peterson Health Technology Institute, is working to fill that gap by evaluating how good some of these tools actually are. Her t...
Breaking down the XBI — with Josh Schimmer 10.09.2025 33:00
Will the XBI ever go up again? Today, we’re posing the intentionally provocative — but revealing — to Cantor’s Josh Schimmer, who has a new analysis out on the index. He’s joining Post-Hoc Live to tell us why, after years of flat numbers, things might be better than they seem.
Choosing the Endpoints 11 03.09.2025 32:40
Each year, the Endpoints newsroom places bets on the 11 private biotech companies that we think are the most promising, the most cutting-edge — and would leave the biggest crater behind if things go belly-up. Wednesday on Post-Hoc Live, we’ll share a behind-the-scenes look at how we pick the Endpoints 11, tease what types of companies we focused on this year, and look back at what’s happened to th...
John Maraganore and Clive Meanwell are coming out of stealth 02.09.2025 38:01
John Maraganore and Clive Meanwell are teaming up again. The two biotech luminaries are coming out of stealth today as co-CEOs of Corsera Health, and have plans to create a two-RNAi drug for cardiovascular disease prevention. They’re joining Post-Hoc Live today to talk about why they’re betting their own money on the venture, their approach to starting companies, and what they think is coming next...
mRNA vs MAHA — with Brett Giroir 12.08.2025 39:58
mRNA-based Covid-19 vaccines were a signature accomplishment under the first Trump administration. But now, RFK Jr. is in charge at HHS, and he’s cutting contracts with mRNA vaccine makers. We’re joined today by Brett Giroir, the assistant secretary for health at HHS under the first Trump administration, to talk about the impact of MAHA’s vaccine agenda — and what the changes mean for the future o...
Getting answers on tariffs, China and Trump: What we learned from Q2 earnings 07.08.2025 33:30
After three weeks of corporate earnings reports, we’ve got a roundup of news and analysis taking in all of the biotech and pharma companies that gave updates. We’ll dig into what big pharma companies are saying about the Trump administration’s tariff, pricing and regulatory moves, how companies are talking about China and what we learned about closely watched results from a few key companies like...
Why China’s biotech boom may be unstoppable 01.08.2025 35:23
Earlier this month, Curie. Bio CEO Zach Weinberg joined Post-Hoc Live to give his take on why he thinks investors should stay away from Chinese biotechs. Today, we’re joined by Cui Cui, the head of Asia healthcare research at Jefferies, to get her perspective on the China biotech boom, and why US pharma companies keep turning to China for their deals (and not to US startups).
The Sarepta mess 29.07.2025 36:50
In the last two weeks, Sarepta has been threatened by the FDA with having its drug pulled, refused to do so, then capitulated, and then won a reversal by the regulator. We'll talk with R.W. Baird analyst Brian Skorney, who has followed the company's ups and downs for years, and what this latest twist tells us about the company's future, how this FDA is operating, and the power of patie...
Sarepta’s very bad week 21.07.2025 34:45
Things don’t look good for Sarepta. After reports of a third patient death on Thursday — this one in a clinical trial — which wasn’t disclosed by the company in its corporate update, an HHS official told Endpoints that the FDA would ask the company to stop shipping its Duchenne muscular dystrophy treatment Elevidys. Stock is down. Leadership is under fire for not being transparent about patient de...
Drugs! In! Space! With Varda Chief Science Officer Adrian Radocea 17.07.2025 33:18
Are drugs in space for real this time? Varda Space Industries, which just announced they had raised $137 million to start industrializing bio-processing in low-earth orbit, certainly thinks so. Endpoints Executive Editor Drew Armstrong and Senior Science Correspondent Ryan Cross are more skeptical — so Varda’s Chief Science Officer Adrian Radocea is joining Post-Hoc Live to try and convince them t...
Is China a threat, or an investment opportunity? Post-Hoc Live with Curie.Bio CEO Zach Weinberg 10.07.2025 42:32
Biopharma companies are increasingly turning to China to find new molecules, and looking to Chinese companies for licensing deals. Some investors are leaning in — but others, like Curie. Bio CEO Zach Weinberg, think they should stay away. This week, Weinberg joins Post-Hoc Live to help us to take stock of the landscape. Be sure to check out our coverage before you tune in: https://endpoints.news/u...
What we learned from RFK’s reconstructed ACIP 27.06.2025 40:38
It’s a busy week in Washington. RFK Jr. faced the House Energy and Commerce Subcommittee on Health. The newly reconstructed ACIP will meet for the first time. And Susan Monarez will go before the Senate Health, Education, Labor, and Pensions Committee for her confirmation hearing to lead the Centers for Disease Control and Prevention. We’ll go live after the final ACIP votes on Thursday, June 26 t...
On the ground at BIO 2025 18.06.2025 32:48
We’re coming to you live from Boston, where Endpoints reporters have spent the past few days at BIO 2025 talking with industry leaders. The mood in the industry has been bleak — how is that playing out on the ground?
What happens if AI gets smarter than we are? 13.06.2025 40:39
Today, Drew Armstrong will be joined by senior biopharma correspondent Andrew Dunn and Abhi Mahajan, a machine learning expert who writes about the intersection of ML and biology at Owl Posting. They'll talk about how AI is evolving, what it’ll mean if (or when) it improves past our ability to understand it, and how that will affect drug development.
The fallout from RFK's gutting of ACIP: Post-Hoc Live with former CDC Director Mandy Cohen 12.06.2025 33:27
HHS Secretary Robert F. Kennedy Jr. fired the CDC's vaccine advisory board known as ACIP, which for years has played a key role in setting US vaccination policy on everything from measles to flu to Covid-19. To assess the fallout, we're speaking with former CDC Director Mandy Cohen, who led the agency from 2023 to 2025.
Ähnliche Podcasts
Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet